A Randomized Phase ll Study of Adjuvant Sunitinib or Valproic Acid in High-Risk Patients With Uveal Melanoma
Phase of Trial: Phase II
Latest Information Update: 30 Oct 2017
At a glance
- Drugs Sunitinib (Primary) ; Valproic acid
- Indications Uveal melanoma
- Focus Therapeutic Use
- 25 Oct 2017 Planned End Date changed from 1 Feb 2019 to 1 Feb 2020.
- 23 Nov 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
- 16 Mar 2014 New trial record